Insulet Corp.
Company Snapshot
Founded: 2000
Entity Type: Public
Employees: 5,400
Region: U.S.
Revenue: $2,708.1 Millions
Revenue Year: 2025
Segment: Omnipod
Headquarter: Acton, Massachusetts, U.S.
Key Geographics: U.S., China, Malaysia
Corporate Address: 100 Nagog Park, Acton, Massachusetts 01720, U.S. Tel. +1-978-600-7000 www.insulet.com
Company Overview
Insulet Corp. specializes in the development, manufacturing, and sale of continuous insulin delivery systems for individuals with insulin-dependent diabetes. It operates through two main segments: Omnipod products and drug delivery.
Insulet Corp. serves the infusion pump and device market through its Omnipod Products segment. The segment includes the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, Omnipod Insulin Management System, and the latest innovation, Omnipod GO. Its products are accessible in over 25 countries across North America, Europe, the Middle East, and the Asia-Pacific.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Insulet Corp. In News
Company's Business Segments
- Omnipod : The Omnipod Insulin Management System (“Classic Omnipod”), The Omnipod DASH Insulin Management System (“Omnipod DASH”), and the Omnipod 5 Automated Insulin Delivery System (“Omnipod 5”)
- Drug Delivery : Drug Delivery consists of sales of pods to Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Applications/End User Industries
- Medicine Manufacturing
- Diabetes
- Patients
- Pharmaceuticals
- Healthcare